New Trial Starts for Patients with Idiopathic Pulmonary Fibrosis

Dr. Martin Kolb, Director of the Division of Respirology at the Department of Medicine at McMaster University​ and an expert on interstitial lung disease​ discusses Horizon Therapeutics‘ Phase 2b pivotal trial to evaluate HZN-825, a lysophosphatidic acid receptor 1 (LPAR1) antagonist to treat people with idiopathic pulmonary fibrosis (IPF), the most common interstitial lung disease

Dr. Martin Kolb is the director of the Division of Respirology at the Department of Medicine at McMaster University and an expert on interstitial lung disease. Dr. Kolb is the primary investigator for Horizon Therapeutics’ Phase 2b clinical trial for HZN-825 in idiopathic pulmonary fibrosis and runs a specialty clinic for interstitial lung diseases and pulmonary fibrosis at St. Joseph’s Healthcare. Dr. Kolb has published more than 80 scientific articles and is Deputy Editor for Respirology and on the Editorial Board of the American Journal of Respiratory and Critical Care Medicine.

Liked it? Take a second to support healthprofessionalradio on Patreon!

0 Comments

Leave a Reply

You must be logged in to post a comment.